Emmaus Life Sciences's quarterly market cap
declined
from Mar. 2023 ($15.41 Mil) to Jun. 2023 ($12.34 Mil) and
declined
from Jun. 2023 ($12.34 Mil) to Sep. 2023 ($6.70 Mil).
Emmaus Life Sciences's annual market cap
increased
from Dec. 2020 ($60.25 Mil) to Dec. 2021 ($82.35 Mil) but then
declined
from Dec. 2021 ($82.35 Mil) to Dec. 2022 ($12.91 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Emmaus Life Sciences's Enterprise Value for Today is $38.77 Mil.
Emmaus Life Sciences Market Cap Historical Data
The historical data trend for Emmaus Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Emmaus Life Sciences's Market Cap
For the Biotechnology subindustry, Emmaus Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Market Cap falls into.
Emmaus Life Sciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Emmaus Life Sciences's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (OTCPK:EMMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Emmaus Life Sciences Market Cap Related Terms
Thank you for viewing the detailed overview of Emmaus Life Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Emmaus Life Sciences (Emmaus Life Sciences) Business Description
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EMMA has been successfully added to your 